Clinical trials: Stereotactic Ablative Radiotherapy
Non-Small Cell Lung Cancer
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
- Trial name
- STABLE-MATES (NCT02468024)
- Testing
- Lung Surgery, Radiation therapy
- Where
- 50 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- University of Texas Southwestern Medical Center
Cancer, Lung, Cancer of Stomach
Investigation of an Abdominal Compression Device
This study is applicable to patients undergoing lower lung or abdomen stereotactic ablative body radiotherapy (SABR) treatment. The purpose of the ACE 01 study is to identify if, the volume of healthy tissue within the treatment…
- Trial name
- ACE02 (NCT04270890)
- Testing
- Abdominal compression belt system
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Prostate Cancer, Radiotherapy Side Effect
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer 2.
- Conditions
- Prostate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac, Stereotactic Ablative RT
- Trial name
- SMART-P01/02 (NCT05183074)
- Testing
- MR-linac
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer
Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer
Radiation can induce immunogenic cell death, local release of inflammatory cytokines, and damage associated molecular patterns (DAMPs) resulting in local effects on endothelial cell expression of adhesion receptors, increased…
- Trial name
- SKYROCKET (NCT05034055)
- Testing
- atezolizumab / tiragolumab
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Yonsei University
Unresectable Malignant Neoplasm, Bulky Tumor
Proton and Proton-Photon Hybrid Partial Stereotactic Ablative Boost Radiotherapy (P-SABR) for Unresectable Large Tumors
This prospective, multicenter, observational cohort study will enroll 60 adults with unresectable larege tumors (longest diameter > 5 cm) who receive one of two treatment modes: (A) proton P-SABR, in which both the proton…
- Conditions
- Unresectable Malignant Neoplasm, Bulky Tumor, Solid Tumor
- Trial name
- LARGE-Proton (NCT07818798)
- Testing
- Proton P-SABR, Proton-Photon Hybrid P-SABR
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Renal Tumor
SABR for Renal Tumors
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for…
- Trial name
- NCT03747133
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Prostate Adenocarcinoma, Prostate Cancer
Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0
The hypo-FLAME 2.0 study is a multicenter phase II study (n=124) investigating the feasibility and safety of a reduction in the overall treatment time of radiotherapy for prostate cancer patients, making use of hypofractionated…
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, Prostate Neoplasm
- Trial name
- NCT04045717
- Testing
- Hypo-FLAME 2.0 study
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 124 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cancer of Pancreas
Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer
A window of opportunity feasibility study assessing pre-operative stereotactic ablative body radiotherapy followed by immediate surgery in pancreatic adenocarcinoma.
- Trial name
- PORTICO-SABR (NCT04128332)
- Testing
- Pre-operative stereotactic ablative body radiotherapy
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- CCTU- Cancer Theme
Post Prostatectomy
Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
In the clinical scenario of recurrent prostate cancer (PCa) post local therapy, current standard studies (bone scan and computed tomography) commonly fail to identify the recurrent disease location.
- Trial name
- PSMA MRgRT (NCT03160794)
- Testing
- [18F]DCFPyL PET/MRI scan, Stereotactic Ablative Radiotherapy
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University Health Network, Toronto
Malignant Lung Neoplasm, Metastatic Malignant Neoplasm in the Lung
CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
This study assesses computed tomography (CT) perfusion imaging in predicting treatment response in patients with non-small cell lung cancer or tumors that have spread from the primary site (place where it started) to the lungs…
- Conditions
- Malignant Lung Neoplasm, Metastatic Malignant Neoplasm in the Lung, Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer
- Trial name
- NCT02693080
- Testing
- CAPP-Seq, Isovue-200, Computed Tomography Perfusion Imaging
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Stanford University
Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
The standard treatment for hepatocellular carcinoma (HCC) is surgery, such as, by hepatic resection or liver transplantation, but less than 20% of HCC patients are suitable for surgery.
- Trial name
- NCT01850667
- Testing
- Stereotactic body radiotherapy
- Where
- 7 sites in South Korea
- Volunteers
- 74 people
- Sponsor
- Korea Cancer Center Hospital
Oligometastases
SABR-SCAN Trial for Pulmonary Oligometastases
Rationale: SABR (Stereotactic ablative radiotherapy) is one of the standard treatment options besides surgical resection for limited lung metastases (oligometastases) from colorectal cancer.
- Trial name
- SABR-SCAN (NCT02414334)
- Testing
- Stereotactic Ablative Radiotherapy (SABR)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Oligometastatic Disease, Bone Metastases
Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease
This is a prospective, investigator-initiated, phase II, multicentre-study, investigating the efficacy and toxicity of definitive SABR of osseous oligometastases, when pragmatically introduced into a daily clinical setting.
- Conditions
- Oligometastatic Disease, Bone Metastases, Stereotactic Body Radiotherapy
- Trial name
- NCT05101824
- Testing
- SABR
- Where
- 6 sites in Denmark, Norway
- Volunteers
- 67 people
- Sponsor
- Gitte Fredberg Persson MD PhD
Prostate Cancer Adenocarcinoma
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
Reduction of dose to or 'sparing' of neurovascular structures during stereotactic ablative body radiotherapy (SAbR) for localized prostate cancer will improve retention of sexual potency, while retaining excellent oncologic…
- Trial name
- POTEN-C (NCT03525262)
- Testing
- 30Gy (Gray) planning target volume (PTV)
- Where
- 8 sites in United States
- Volunteers
- 124 people
- Sponsor
- University of Texas Southwestern Medical Center
Cancer
CPAP for Motion Management in Breast Radiotherapy; and Lung & Liver SABR
A phase II trial to determine the proportion of patients where the use of continuous positive airway pressure (CPAP) results in a superior radiation plan compared to standard planning procedures.
- Trial name
- CPAP-RT (NCT05396950)
- Testing
- CPAP
- Volunteers
- 70 people
- Sponsor
- Waikato Hospital
Non-small Cell Lung Cancer
Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial
The goal of this clinical trial is to learn if first-line Almonertinib plus upfront stereotactic ablative body radiotherapy (SABR) works to treat EGFR-mutated advanced non-small cell lung cancer.
- Trial name
- NCT06481566
- Testing
- stereotactic ablative body radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital